Moderna announces 94.5% efficacy for COVID-19 vaccine
Editor's Note Moderna Inc (Cambridge, Massachusetts) on November 16 announced that its vaccine is 94.5% effective at preventing COVID-19. Their analysis of a 30,000-person trial (half received the vaccine and half received a placebo) finds that 90 of the 95 COVID-19 documented cases are in the placebo group. The Moderna announcement…
CMS issues coverage plan for COVID-19 vaccines, treatments
Editor's Note The Centers for Medicare and Medicaid Services (CMS) on October 28 issued an interim final rule that requires CMS to cover any COVID-19 vaccines that receive Food and Drug Administration (FDA) authorization at no cost to beneficiaries. The rule also will increase what Medicare pays hospitals for COVID-19…
Simulation to predict hospital capacity needs during COVID-19 pandemic
Editor's Note This study from the University of Pennsylvania, Philadelphia, finds that a susceptible, infected, removed (SIR) epidemic model can be adapted to local population characteristics to inform hospital planning for epidemic-related surges in hospital capacity. Using COVID-19 patients only, the SIR model estimated that it would be 31 to…
Free Daily News
- Kentucky Derby, SPD race: Leadership lessons energized SPD professionals at HSPA 2025
- Continuum-based protocol offers new strategy for preventing PONV after thyroidectomy
- Pembrolizumab sets new standard in advanced head and neck cancer surgery, trial shows
- Subarachnoid spinal anesthesia offers safe, effective option for high-risk obstetric patients
- Same-day discharge after catheter ablation gains backing from top cardiology societies
- Tenet, HCA post strong Q1 results, but caution looms over policy uncertainty, outpatient trends
- Telemedicine transforms postoperative care through safer, faster, patient-centered recovery
- ASCA conference coverage to keep ASC leaders informed
- Study: Prolonged COVID symptoms more likely for healthcare workers
- Study: Patients of female surgeons experience fewer complications, lower long-term readmission